RESUMO
Vaccination is one of the most powerful measures to control infectious diseases. Nowadays, technical advances allowed the recognition of key aspects of pathogen -host interaction and the spread of such information, which was applied in vaccine development. The urge to control the COVID-19 pandemic resulted in vaccines development in record time, approximately 1 year after the emergence of SARS-CoV-2. The use of classic and innovative vaccine platforms and adjuvants was employed at several locations, by different groups. Here, we discuss how the pandemic scenario influences vaccine development, the implications of the route of immunization and adjuvant choice for vaccines, and the need to consider all these aspects in relation to the current scenario, also preparing ourselves to future pandemics. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.
RESUMO
Antibody production in response to infection or vaccination is a crucial process to combat and prevent infectious diseases. Regarding SARS-CoV-2, different features have been observed and literature still lacks consensus about it. Here, we discuss the production of antibodies during SARS-CoV-2 infection and its therapeutic relevance. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.